Psygen is a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications. With 25 clients, Psygen is set to become one of the leading contract development & manufacturers (CDMO) in the psychedelic space.
Psygen
Psygen hopes to have its first product on the market in 2022. To do so, the company has received a Dealer’s Licence from Health Canada.
Psygen is already working together with leading psychedelics companies such as Beckley Psytech (who’s developing 5-MeO-DMT for depression), Neonmind, and Wesana.
Activities
B2B
B2C
Manufacturing
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates